HUTCHMED (NASDAQ:HCM) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• HUTCHMED has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, reflecting a change in analyst sentiment.
• Despite the downgrade, Zacks Research maintains a "strong-buy" rating for the stock, indicating mixed opinions among analysts with an average target price of $28.00.
• HUTCHMED's stock performance shows a one year low of $11.51 and a high of $21.50, with the stock opening at $15.97 recently.

Wall Street Zen lowered shares of HUTCHMED (NASDAQ:HCM - Free Report) from a buy rating to a hold rating in a research report released on Sunday.

HCM has been the subject of several other research reports. HSBC cut HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Bank of America increased their price target on HUTCHMED from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Finally, Zacks Research raised HUTCHMED to a "strong-buy" rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $28.00.

HUTCHMED Price Performance

Shares of HUTCHMED stock traded down $0.34 during trading on Friday, hitting $15.71. The company's stock had a trading volume of 75,436 shares, compared to its average volume of 80,190. The stock has a 50-day moving average price of $16.41 and a two-hundred day moving average price of $15.39. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $21.50.

Institutional Trading of HUTCHMED

A number of institutional investors have recently bought and sold shares of HCM. Barclays PLC boosted its position in HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after acquiring an additional 2,255 shares during the last quarter. Jane Street Group LLC boosted its position in shares of HUTCHMED by 54.7% during the 4th quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock worth $1,405,000 after purchasing an additional 34,473 shares in the last quarter. Bank of America Corp DE boosted its position in shares of HUTCHMED by 40.4% during the 4th quarter. Bank of America Corp DE now owns 22,723 shares of the company's stock worth $327,000 after purchasing an additional 6,540 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of HUTCHMED by 49.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after purchasing an additional 899 shares in the last quarter. Finally, Summit Trail Advisors LLC boosted its position in shares of HUTCHMED by 7.7% during the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock worth $212,000 after purchasing an additional 1,004 shares in the last quarter. Institutional investors own 8.82% of the company's stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.